1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Cough Suppressant Pholcodine Set For EU-Wide Ban

 
• By Tom Gallen

Safety concerns have led a European Medicines Agency committee to recommend the withdrawal of marketing authorizations for all pholcodine-containing drugs sold in the EU, including both OTC and Rx presentations.

Rubber stamping that says 'Withdrawn'.
• Source: Shutterstock

Cough suppressants containing pholcodine look set to be banned from OTC and prescription sale across the EU over concerns their use may increase the risk of an anaphylactic reaction to drugs used in general anesthesia.

Following a safety review initiated earlier this year, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has recommended the revocation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.